Dongkoo Bio&Pharma strengthens dermatology lineup with ‘Betatriol’

Published: 2017-02-09 13:34:52

Updated: 2017-02-09 13:39:02

After successfully avoiding the patent of the psoriasis treatment ‘Daivobet(Product name of Dongkoo Bio&Pharma: Betatriol),’ Dongkoo Bio&Pharma(CEO Yong-Jun Cho) is actively working on commercialization of its product.

The Intellectual Property Tribunal raised the hand of Dongkoo at the patent nullity suit and confirmation trial of the scope filed by Dongkoo Bio&Pharma against Leo Pharma on th...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.